Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia.
Antiviral
Cohort
Comorbidity
SARS-Cov-2
Severity
Survival
Journal
The Lancet regional health. Southeast Asia
ISSN: 2772-3682
Titre abrégé: Lancet Reg Health Southeast Asia
Pays: England
ID NLM: 9918419282806676
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
19
05
2022
revised:
31
01
2023
accepted:
01
02
2023
pubmed:
15
2
2023
medline:
15
2
2023
entrez:
14
2
2023
Statut:
ppublish
Résumé
Indonesia had the second-highest number of COVID-19 cases and deaths in South-East Asia. We aimed to determine the factors associated with this mortality and the effect of the recommended COVID-19 treatment regimen during the first 10 months of the epidemic. This was a retrospective cohort study using secondary data from medical records. In total, 689 adult COVID-19 inpatients hospitalized between March and December 2020 were enrolled. Clinical characteristics, laboratory parameters, and treatments were analyzed by survival outcome. Kaplan-Meier statistics were used to estimate survival. Of the 689 patients enrolled, 103 (14.9%) died. Disease severity was highly associated with mortality (hazard ratio [HR]: 7.69, Older age and comorbidities were associated with disease severity and, consequently, higher mortality. Higher mortality after the second week of hospitalization may be related to secondary bacterial infection. Favipiravir showed significant benefit for COVID-19 survival, while steroids showed benefit only in the early days of admission among patients with severe disease. This research did not receive a specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Sections du résumé
Background
UNASSIGNED
Indonesia had the second-highest number of COVID-19 cases and deaths in South-East Asia. We aimed to determine the factors associated with this mortality and the effect of the recommended COVID-19 treatment regimen during the first 10 months of the epidemic.
Methods
UNASSIGNED
This was a retrospective cohort study using secondary data from medical records. In total, 689 adult COVID-19 inpatients hospitalized between March and December 2020 were enrolled. Clinical characteristics, laboratory parameters, and treatments were analyzed by survival outcome. Kaplan-Meier statistics were used to estimate survival.
Findings
UNASSIGNED
Of the 689 patients enrolled, 103 (14.9%) died. Disease severity was highly associated with mortality (hazard ratio [HR]: 7.69,
Interpretation
UNASSIGNED
Older age and comorbidities were associated with disease severity and, consequently, higher mortality. Higher mortality after the second week of hospitalization may be related to secondary bacterial infection. Favipiravir showed significant benefit for COVID-19 survival, while steroids showed benefit only in the early days of admission among patients with severe disease.
Funding
UNASSIGNED
This research did not receive a specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Identifiants
pubmed: 36785545
doi: 10.1016/j.lansea.2023.100167
pii: S2772-3682(23)00027-6
pmc: PMC9910028
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100167Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
We declare that we have no competing interests.
Références
Int J Gen Med. 2022 May 06;15:4741-4751
pubmed: 35571285
Lancet Reg Health West Pac. 2021 Apr;9:100108
pubmed: 33681830
PLoS One. 2020 Dec 14;15(12):e0243343
pubmed: 33315929
Am J Emerg Med. 2021 Mar;41:110-119
pubmed: 33418211
Diabetes Care. 2009 Jan;32 Suppl 1:S62-7
pubmed: 19118289
Front Med (Lausanne). 2021 Jan 13;7:563893
pubmed: 33521006
J Infect Public Health. 2021 May;14(5):570-576
pubmed: 33848886
Acta Med Indones. 2020 Jul;52(3):199-205
pubmed: 33020331
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):303-310
pubmed: 32298981
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
JAMA. 2018 Nov 6;320(17):1749-1750
pubmed: 30398611
Clin Microbiol Infect. 2020 Jun;26(6):767-772
pubmed: 32304745
Lancet Microbe. 2020 May;1(1):e11
pubmed: 32835323
Am J Med. 2021 Jan;134(1):e6-e14
pubmed: 32653423
Ann Intern Med. 2021 Jan;174(1):125-127
pubmed: 32687717
Clin Infect Dis. 2005 Nov 15;41 Suppl 7:S504-12
pubmed: 16237654
PLoS One. 2021 Mar 23;16(3):e0249090
pubmed: 33755688
Kidney Int. 2005 Jun;67(6):2089-100
pubmed: 15882252
BMC Public Health. 2020 Oct 27;20(1):1616
pubmed: 33109136
Curr Pharmacol Rep. 2020;6(3):56-70
pubmed: 32395418
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Disaster Med Public Health Prep. 2022 Oct;16(5):1916-1921
pubmed: 33762058
Expert Rev Hematol. 2020 Aug;13(8):787-793
pubmed: 32580592
Int J Antimicrob Agents. 2020 Aug;56(2):106051
pubmed: 32534186
Clin Infect Dis. 2021 Dec 6;73(11):2031-2036
pubmed: 34111274
Intervirology. 2020 Dec 9;:1-12
pubmed: 33296901
Int Immunopharmacol. 2020 Jul;84:106504
pubmed: 32304994
Acta Med Indones. 2020 Jul;52(3):246-254
pubmed: 33020335
Clin Chim Acta. 2020 Jun;505:190-191
pubmed: 32145275
Infect Dis Ther. 2021 Dec;10(4):2489-2509
pubmed: 34453234
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
J Pers Med. 2022 May 26;12(6):
pubmed: 35743662